



**Biocon Limited**  
20th KM, Hosur Road  
Electronic City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

[www.biocon.com](http://www.biocon.com)

October 4, 2021

To, The Manager <b>BSE Limited</b> Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <b>Scrip Code – 532523</b>	To, The Manager <b>National Stock Exchange of India Limited</b> Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 <b>Scrip Symbol - Biocon</b>
--	---

**Subject: Press Release titled “Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US.”**

Dear Sir/Madam,

Please find enclosed the press release titled “**Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US.**”

The above information will also be available on the website of the Company at [www.biocon.com](http://www.biocon.com).

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

*Mayank*



**Mayank Verma**  
**Company Secretary and Compliance Officer**

**Enclosed: Press Release**



## PRESS RELEASE

### **Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US**

**Bengaluru, India and Iselin, NJ, USA. October 4, 2021.**

Biocon Ltd (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company today announced the launch of Everolimus tablets, a generic version of Afinitor<sup>®</sup>, in the US.

Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet being a 'day-1' generic launch. Everolimus (Afinitor<sup>®</sup>) is a prescription medication that is used to treat certain types of cancers and tumours.

The commercial launch of Everolimus follows an US FDA approval in February 2021.

Siddharth Mittal, Chief Executive Officer & Managing Director, said, *"The launch of Everolimus tablets is another important addition to our generics portfolio and underscores our commitment to bringing complex, vertically integrated and affordable generic formulations to the market expeditiously. We will continue our focus on innovation and enhancing capacities to launch new products that make affordable healthcare accessible to millions of patients the world over."*

The Everolimus launch is further assertion of Biocon's strategy to focus on vertically integrated, complex Finished Dosage Formulations (FDF) in niche therapeutic areas, using in-house Active Pharmaceutical Ingredient (API) capabilities.

According to IQVIA, US sales of Everolimus (Afinitor<sup>®</sup>) tablets of 2.5mg, 5mg, 7.5mg, and 10mg strengths were approximately \$675 million in the 12 months ending July 2021.

Afinitor<sup>®</sup> is a registered trademark of Novartis AG.

~~~~~

**About Biocon Limited:** Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. **[www.biocon.com](http://www.biocon.com)**

**Disclaimer:** *This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition and the conditions of the Indian and global biotechnology and pharmaceuticals industries,*



*changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.*

|                                  |                                |
|----------------------------------|--------------------------------|
| <b>Media Relations</b>           | <b>Investor Relations</b>      |
| BIOCON LIMITED                   | BIOCON LIMITED                 |
| Calvin Printer +91 80 2808 2132  | Chirag Dalal +91 80 2808 2070  |
| Email: calvin.printer@biocon.com | Email: chirag.dalal@biocon.com |